Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

LY2603618

SKU: orb1301087
FeaturedFeatured Product

Description

Rabusertib (IC-83) is a selective checkpoint kinase 1 (Chk1) inhibitor investigated for its chemosensitizing potential in oncology research. It has been evaluated in preclinical and clinical studies for solid tumors, including pancreatic and non-small cell lung cancers, to enhance the efficacy of DNA-damaging chemotherapeutic agents.

Research Area

Cell Biology

Images & Validation

−
LY2603618

Key Properties

−
CAS Number911222-45-2
MW436.30
Purity>98%
FormulaC18H22BrN5O3
SMILESCc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1
TargetKinase
SolubilitySoluble in DMSO (up to 10 mg/ml)

Bioactivity

−
Target IC50
CaMK II:1550 nM|PDK1:893 nM|Chk1:7 nM|NTRK1:12000 nM|VEGFR3:2128 nM|RSK2:5700 nM|JNK1:4930 nM|MET:2200 nM|Chk2:12000 nM
In Vivo
In xenograft models, LY2603618 delays tumor growth when given in combination with pemetrexed.
In Vitro
Chk1 is an ATP-dependent serine-threonine kinase and a key component in the DNA replication-monitoring checkpoint system activated by double-stranded breaks (DSBs). Chk1 contributes to all currently defined cell cycle checkpoints, including G1/S, intra-S-phase, G2/M, and the mitotic spindle checkpoint. By inhibiting the activity of chk1, Rabusertib prevents the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. However, preClinicalal data involving Rabusertib has not been published until now. Inhibition of Chk1 is predicted to enhance the effects of antimetabolites, such as gemcitabine. Rabusertib treatment impairs DNA synthesis, increases DNA damage (via mitotic defects), induces apoptosis, and has synergistic activity with pemetrexed, especially in p53 mutant tumor cells.
Read more...
Cell Research
LY2603618 is prepared in DMSO (10 mM) and stock, and then diluted 1000-fold into medium. Cells are plated at 2.5×103 per well, on 96-well tissue culture plates and incubated for one cell doubling (18-24 h). Gemcitabine dilutions are set up by half-log steps across a final concentration range of 1-1000 nM. LY2603618 is prepared by dilutions in DMSO to 5000× final concentration, and then diluted 1000-fold into medium to generate 5× stocks for addition to wells. Approximately 24 h after Gemcitabine addition, LY2603618 is added. Each combination is done in triplicate. After a period of two cell doublings following LY2603618 addition, MTS/PMS reagent is added to each well according to the manufacturer's instructions. Absorbance is read on a Spectra Max 250 spectrophotometer at 490 nm and the data analyzed with GraphPad Prism 4.0. Dose-response curves are fit by non-linear regression, with bottom fits constrained to 0 % inhibition.
Read more...

Storage & Handling

−
Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
Rabusertib

Similar Products

−
  • GDC-0575

    GDC-0575 [orb1226825]

    >98% (HPLC)

    1196541-47-5

    377.286

    C17H21BrN4O

    25 mg, 10 mg, 5 mg, 50 mg, 100 mg, 1 g, 500 mg, 200 mg
  • LY2603618

    LY2603618 [orb1223677]

    >98% (HPLC)

    911222-45-2

    436.303

    C18H22BrN5O3

    1 g, 200 mg, 500 mg, 5 mg, 10 mg, 2 mg, 25 mg, 100 mg, 50 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Compound Identifiers

PubChem CID
11955855 ↗

Key Properties

−
No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Find More Protocols

LY2603618 (orb1301087)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Login to review

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
$ 170.00
25 mg
$ 340.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry
Need technical support? Find your Distributor Return and Tax Policy

Email

info@biorbyt.com

UK Office

+44 (0)1223 859353

US Office

+1 (415) 906-5211

CN Office

+86 (27)-87663101

Distributors

biorbyt.com/distributor